<DOC>
	<DOCNO>NCT01572662</DOCNO>
	<brief_summary>The goal clinical research study learn give busulfan fludarabine stem cell transplant help control disease good standard method patient leukemia , lymphoma , multiple myeloma , MDS , MPD . In study , 2 dos busulfan give 2 week stem cell transplant follow 4 dos busulfan fludarabine week stem cell transplant , rather standard method give 4 dos busulfan fludarabine week stem cell transplant . The safety combination therapy also study . Busulfan design kill cancer cell bind DNA ( genetic material cell ) , may cause cancer cell die . Busulfan commonly use stem cell transplant . Fludarabine design interfere DNA cancer cell , may cause cancer cell die .</brief_summary>
	<brief_title>Allogeneic Transplantation Using Timed Sequential Busulfan Fludarabine Conditioning</brief_title>
	<detailed_description>Central Venous Catheter : If choose take part study , chemotherapy , drug study , stem cell transplant give vein central venous catheter ( CVC ) . A CVC sterile flexible tube needle place large vein local anesthesia . Blood sample also draw CVC . The CVC remain body treatment . Your doctor explain procedure detail , require sign separate consent form . Study Drug Administration Procedures : For stem cell transplant , day receive stem cell call minus day . The day receive stem cell call Day 0 . The day receive stem cell call plus day . You receive dose busulfan vein 3 hour Day -13 Day -12 . With Day -13 busulfan infusion , 11 sample blood ( 1-2 teaspoon time ) drawn pharmacokinetic ( PK ) test various time point receive first dose busulfan . The study staff tell blood test schedule . PK test measure amount study drug body different time point . The PK test help doctor decide dose busulfan Days -6 -3 . If need , PK blood test may also do Day -6 dose Busulfan . You may receive Day -13 Day -12 busulfan dose either outpatient clinic inpatient hospital . A heparin lock line place vein low number needle stick need draws . If possible PK test perform technical reason , take study receive standard fix dose busulfan . On Days -13 -12 , receive busulfan vein 3 hour . On Days -11 -7 , rest . On Days -6 -3 , receive fludarabine vein 1 hour , busulfan vein 3 hour . On Days -2 -1 , rest . On Day 0 , receive stem cell transplant vein . After transplant , receive tacrolimus , methotrexate , drug weaken immune system standard manner low risk graft-vs-host disease ( GVHD ) , reaction donor 's immune cell recipient 's body . You receive tacrolimus vein nonstop infusion able take mouth help low risk GVHD . You take tacrolimus mouth 2 time day 3 month . After , tacrolimus dose may lower GVHD . Your doctor discus . On Days 1 , 3 , 6 , stem cell relate match unrelated donor , receive methotrexate 30 minute day vein help low risk GVHD . Participants receive match unrelated donor also receive methotrexate Day 11 transplant . You receive filgrastim injection skin 1 time day , start 1 week transplant , blood cell level return normal . Filgrastim design help growth white blood cell . Study Testing : While hospital , check side effect part standard care . Blood ( 2 teaspoon ) draw every day check side effect , routine test , check blood count , kidney liver function , check infection . As part standard care , remain hospital 3-4 week transplant . After send home hospital , must remain Houston area check infection transplant side effect 3 month transplant . During time , return clinic least 1 time week . The following test procedure perform : - You ask feel side effect may . - Blood ( 2 teaspoon ) draw routine test . About 1 , 3 , 6 , 12 month transplant : - You physical exam , include measurement vital sign ( blood pressure , heart rate , temperature , breathe rate ) . - You ask feel side effect may . - Blood ( 5 teaspoon ) drawn see well transplant `` take . '' - You bone marrow aspiration check status disease , doctor think need . To collect bone marrow aspiration , area hip site numb anesthetic , small amount bone marrow withdrawn large needle . Length Study : You take study 3 year end treatment . You may take study early disease get bad , intolerable side effect , unable follow study direction . You talk study doctor want leave study early . If take study early , still may need return routine follow-up visit transplant , transplant doctor decides need . It may life-threatening leave study begin receive study drug receive stem cell . This investigational study . Busulfan fludarabine FDA approve commercially available . The investigational part study addition 2 dos busulfan . Up 200 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Patients highrisk hematologic malignancy anticipate poor prognosis non transplant therapy , include remission induction failure treat untreated relapse . Diagnoses include ) Acute myeloid leukemia ; b ) Acute lymphocytic leukemia ; c ) Chronic myeloid leukemia ; ) Chronic lymphocytic leukemia ; e ) Myelodysplastic syndrome ; f ) Myeloproliferative syndrome ; g ) NonHodgkins lymphoma ; h ) Hodgkins Lymphoma ; ) Multiple myeloma . 2 . Patients must histocompatible stem cell donor . An HLAidentical related donor 8/8 match unrelated donor . 3 . Age 5 75 year old . 4 . Performance score &gt; /= 70 Karnofsky/Lansky PS 0 1 ( ECOG &lt; /=1 ) . 5 . Left ventricular ejection fraction least 40 % . 6 . Adequate pulmonary function FEV1 , FVC DLCO &gt; /=50 % expect corrected hemoglobin and/or volume . Children unable perform pulmonary function test ( e.g. , less 7 year old ) pulse oximetry &gt; /= 92 % room air 7 . Creatinine clearance ( calculated creatinine clearance permit ) &gt; 40 ml/min . 8 . Bilirubin &lt; /= 2 x upper limit normal ( except Gilbert 's Syndrome ) . SGPT ( ALT ) &lt; 200 . 9 . Negative Beta HCG test woman child bear potential , define postmenopausal 12 month previous surgical sterilization . Women child bear potential must willing use effective contraceptive measure study . 10 . Patient patient 's legal representative , parent ( ) guardian able sign inform consent . 1 . HIV seropositivity . 2 . Uncontrolled infection .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>Acute lymphocytic leukemia</keyword>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>Myeloproliferative Diseases</keyword>
	<keyword>Non-Hodgkins Lymphoma</keyword>
	<keyword>Hodgkins lymphoma</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Fludarabine monophosphate</keyword>
	<keyword>Fludarabine phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Stem cell transplant</keyword>
	<keyword>Allogeneic Transplantation</keyword>
</DOC>